Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerDHILLON, Sohita.Drugs (Basel). 2013, Vol 73, Num 5, pp 475-485, issn 0012-6667, 11 p.Article

ORAL PHARMACOKINETIC STUDY OF EXEMESTANE SMEDDS AND SUSPENSION IN RAT PLASMA BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRIC ANALYSISSINGH, Ajeet; CHAURASIYA, Akash; WARSI, Musarrat H et al.Journal of liquid chromatography & related technologies. 2012, Vol 35, Num 13-16, pp 2162-2174, issn 1082-6076, 13 p.Article

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031ELLIS, Matthew J; SUMAN, Vera J; ESSERMAN, Laura J et al.Journal of clinical oncology. 2011, Vol 29, Num 17, pp 2342-2349, issn 0732-183X, 8 p.Article

Detection of new exemestane metabolites by liquid chromatography interfaced to electrospray-tandem mass spectrometryDE ALBUQUERQUE CAVALCANTI, Gustavo; CARIUS GARRIDO, Bruno; DIAS LEAL, Felipe et al.Journal of steroid biochemistry and molecular biology. 2011, Vol 127, Num 3-5, pp 248-254, issn 0960-0760, 7 p.Article

Cancer du sein = Breast cancerPIERGA, J. Y; DIERAS, V.La Lettre du cancérologue (Boulogne). 2011, Vol 20, Num 6, issn 1165-113X, 12-21 [8 p.], SUP3Article

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T CellsVONDERHEIDE, Robert H; LORUSSO, Patricia M; USARI, Tiziana et al.Clinical cancer research (Print). 2010, Vol 16, Num 13, pp 3485-3494, issn 1078-0432, 10 p.Article

Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan SubstudyAIHARA, T; SUEMASU, K; TAKEI, H et al.Oncology. 2010, Vol 79, Num 5-6, pp 376-381, issn 0030-2414, 6 p.Article

Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trialMAURIAC, Louis; ROMIEU, Gilles; BINES, José et al.Breast cancer research and treatment. 2009, Vol 117, Num 1, pp 69-75, issn 0167-6806, 7 p.Article

Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancerCHOW, Louis Wing-Cheong; YIP, Adrian Yun-San; LOO, Wings Tjing-Yung et al.Journal of steroid biochemistry and molecular biology. 2008, Vol 111, Num 1-2, pp 13-17, issn 0960-0760, 5 p.Article

Premenopausal endocrine-responsive early breast cancer : who receives chemotherapy?REGAN, M. M; PAGANI, O; CASTIGLIONE-GERTSCH, M et al.Annals of oncology. 2008, Vol 19, Num 7, pp 1231-1241, issn 0923-7534, 11 p.Article

Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With CelecoxibDIRIX, Luc Yves; IGNACIO, Jorge; ABBATTISTA, Antonello et al.Journal of clinical oncology. 2008, Vol 26, Num 8, pp 1253-1259, issn 0732-183X, 7 p.Article

Exémestane et hormonthérapies adjuvantes : perspectivesLUPORSI, Elisabeth.La Lettre du cancérologue (Boulogne). 2008, Num DEC, pp 4-6, issn 1165-113X, 3 p., NSArticle

Effects of third generation aromatase inhibitors on bone health and other safety parameters : Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal womenMCCLOSKEY, Eugene V; HANNON, Rosemary A; LAKNER, Geza et al.European journal of cancer (1990). 2007, Vol 43, Num 17, pp 2523-2531, issn 0959-8049, 9 p.Article

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer : effects on body composition and lipidsFRANCINI, G; PETRIOLI, R; MONTAGNANI, A et al.British journal of cancer. 2006, Vol 95, Num 2, pp 153-158, issn 0007-0920, 6 p.Article

Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer : current and future prospectsJONAT, Walter; HILPERT, Felix.Journal of cancer research and clinical oncology. 2006, Vol 132, Num 6, pp 343-355, issn 0171-5216, 13 p.Article

A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulationVALLE, Marta; DI SALLE, Enrico; JANNUZZO, Maria Gabriella et al.British journal of clinical pharmacology. 2005, Vol 59, Num 3, pp 355-364, issn 0306-5251, 10 p.Article

The use of aromatase inhibitors in adjuvant therapy for early breast cancerJONAT, Walter; HILPERT, Felix; MAASS, Nicolai et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, issn 0344-5704, s32-s38, SUP1Article

Effects of Exemestane and tamoxifen in a postmenopausal breast cancer modelJELOVAC, Danijela; MACEDO, Luciana; HANDRATTA, Venkatesh et al.Clinical cancer research. 2004, Vol 10, Num 21, pp 7375-7381, issn 1078-0432, 7 p.Article

Aromatase inhibitors in breast cancerSMITH, Ian E; DOWSETT, Mitch.The New England journal of medicine. 2003, Vol 348, Num 24, pp 2431-2442, issn 0028-4793, 12 p.Article

Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: Results from a randomised trial of exemestane vs megestrol acetateMARTINETTI, Antonia; ZILEMBO, Nicoletta; SEREGNI, Ettore et al.Anticancer research. 2003, Vol 23, Num 4, pp 3485-3491, issn 0250-7005, 7 p.Article

Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancerVERMA, Shailendra; ROCCHI, Angela.Supportive care in cancer. 2003, Vol 11, Num 11, pp 728-734, issn 0941-4355, 7 p.Article

Clinical differences among the aromatase inhibitors. DiscussionsLIGIBEL, Jennifer A; WINER, Eric P; JOHNSTON, Stephen et al.Clinical cancer research. 2003, Vol 9, Num 1, pp 473s-479s, issn 1078-0432, 2Conference Paper

The impact of hormonal treatments on quality of life of patients with metastatic breast cancerCOSTANTINO, Joseph.Clinical therapeutics. 2002, Vol 24, pp C26-C42, issn 0149-2918, SUPCArticle

Aromatase inhibitorsCUNNICK, G. H; MOKBEL, K.Current medical research and opinion. 2001, Vol 17, Num 3, pp 217-222, issn 0300-7995Article

Inhibiteurs de l'aromatase dans le traitement du cancer du sein = Aromatase inhibitors in breast cancer treatmentPEREY, L.Revue médicale de la Suisse romande. 2000, Vol 120, Num 6, pp 495-500, issn 0035-3655Article